NCT06780592View on ClinicalTrials.gov

Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 13, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Glioblastoma
Interventions
DRUG

Vebreltinib + Temozolomide

Vebreltinib is a capsule in the form of 25 mg and 100mg, twice daily. Participants received Vebreltinib (300 mg Bid) in combination with Temozolomide (150 mg/ m2) treatment, every 4 weeks for up to 6 cycles (Induction).

DRUG

Temozolomide

Participants received Temozolomide (150 mg/ m2) treatment, every 4 weeks for up to 6 cycles (Induction).

All Listed Sponsors
collaborator

Beijing Tiantan Hospital

OTHER

collaborator

Beijing Sanbo Brain Hospital

OTHER

lead

Huashan Hospital

OTHER

NCT06780592 - Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery | Biotech Hunter | Biotech Hunter